
    
      Phase I Primary Objective:

        -  Determine the MTD of Aroplatin/capecitabine subjects with unresectable local recurrence
           or distant metastases of colorectal cancer refractory to 5-FU/LV and irinotecan.

      Phase II Primary Objective:

        -  Evaluate the response proportion and duration with Aroplatin/capecitabine therapy.

      Phase II Secondary Objective:

        -  Evaluate the frequency of adverse events.
    
  